Sells pressure-enabled infusion devices such as TriNav to hospitals and interventional radiologists for tumor-treatment procedures, and develops an investigational immunotherapy for solid tumors.
10-K for FY2025, filed Mar 5, 2026Our delivery method, Pressure-Enabled Drug Delivery (“PEDD”), modulates pressure and flow within blood vessels to improve intravascular…View ↗
It is U.S. Food and Drug Administration ("FDA")-cleared and has undergone peer-reviewed studies at multiple clinical sites. The PEDD method…View ↗
We are currently studying the ability of nelitolimod, an investigational class C TLR9 agonist, to reactivate the immune system within the…View ↗
We have established a commercial infrastructure designed to drive TriNav adoption among interventional radiologists and oncologists. Our…View ↗
Hospitals and clinics buy PEDD infusion systems by purchase order; TriSalus is paid when the products ship, or when they arrive if the order specifies destination delivery. Some hospitals receive products on consignment and pay when they use them and submit a purchase order.
10-K for FY2025, filed Mar 5, 2026Our revenue is derived from the shipments of our PEDD infusion systems to our customers. Our customers are generally comprised of hospitals…View ↗
1.Identify the contract — We do not maintain long-term contracts with our customers. Typically, customers will submit a purchase order to…View ↗
5.Recognize revenue — We recognize revenue at the point-in-time when the units for a purchase order have been shipped and control of the…View ↗
The use of TriNav is consistent with the current steps an interventional radiologist utilizes to conduct TACE and TARE and other…View ↗
$45.2M
10-K for FY2025, filed Mar 5, 2026
$45.2M ↗
Hospitals and ambulatory surgery centers buy directly through TriSalus’s sales organization, while clinicians and hospital staff use or recommend the products. Sales focus is on hospitals and academic medical centers that perform embolization procedures.
10-K for FY2025, filed Mar 5, 2026We aim to interact closely with all our key stakeholders to ensure a patient’s experience is beneficial. We view our customers as including…View ↗
We have established a commercial infrastructure designed to drive TriNav adoption among interventional radiologists and oncologists. Our…View ↗
Our sales representatives, clinical specialists and sales leaders have substantial medical device sales experience and market our products…View ↗
No. It lost $39.2M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$8.9MView ↗
8-K, filed Nov 10, 2026
Revised 2026 revenue guidance to $46 million to $48 millionView ↗
From blank-check search to medical technology
The older report describes a company seeking a healthcare business combination; the latest report describes a medical-technology business selling PEDD infusion systems for tumor procedures.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 5, 2026We are an early stage blank check company formed on September 11, 2020 as a Delaware corporation for the purpose of effecting an initial…View ↗
Competes with Embolix and Merit Medical
10-K for FY2025, filed Mar 5, 2026Microcatheters are manufactured by a wide range of medical device manufacturers. Besides the standard microcatheter, there are two other…View ↗
Loading...